Literature DB >> 15318861

Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17.

G A Denomme1, G Ryan, P G R Seaward, E N Kelly, B J Fernandes.   

Abstract

BACKGROUND: Clinically significant antibodies to high-incident antigens present a challenge in hemolytic disease of the newborn. Antigen-negative blood may be difficult to obtain for intrauterine transfusion (IUT). In these instances, maternal blood is de facto compatible regardless of an ABO mismatch. CASE REPORT: A group B/D-- woman with a history of hemolytic disease of the newborn due to anti-Rh17 (titer 256) presented to the obstetrical clinic at 12 weeks gestation for management of her third pregnancy. She consented to donate blood for possible IUT. STUDY DESIGN AND METHODS: Washed maternal packed cells were suspended in saline to 75 percent Hct and irradiated before transfusion. The fetus was transfused via the intrahepatic vein.
RESULTS: Ultrasound examination at 19 weeks indicated a hydropic fetus. The fetal blood group was O Rh+, direct antiglobulin test 4+, and hemoglobin 22 g per L. A total of 368 mL of maternal blood was transfused during seven procedures. Labor was induced at 38 weeks, and a 2560-g male infant was delivered by Caesarian-section due to fetal distress. The infant grouped as B Rh+, direct antiglobulin test negative. No group O red blood cells were detected. The hemoglobin level was 143 g per L rising to 209 g per L at discharge 3 days later. The indirect bilirubin was 55 micromol/L and remained stable during the hospital stay. Phototherapy was discontinued after 1 day, and the infant was discharged without an exchange or top-up transfusion.
CONCLUSIONS: Maternal ABO-mismatched blood is an alternate source for IUT in instances when antigen-compatible allogenic blood is unavailable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318861     DOI: 10.1111/j.1537-2995.2004.04082.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D-- phenotype.

Authors:  Kazuya Mimura; Masayuki Endo; Atsushi Takahashi; Yohei Doi; Mikiko Sakuragi; Tomoko Kiyokawa; Hidetoshi Taniguchi; Yasuji Kitabatake; Mika Handa; Takuji Tomimatsu; Yoshiaki Tomiyama; Yoshitaka Isaka; Tadashi Kimura
Journal:  Int J Hematol       Date:  2019-09-19       Impact factor: 2.490

Review 3.  The Outcome of Hemolytic Disease of the Fetus and Newborn Caused by Anti-Rh17 Antibody: Analysis of Three Cases and Review of the Literature.

Authors:  Slavica Dajak; Nina Ipavec; Mia Cuk; Branka Golubic Cepulic; Jela Mratinovic-Mikulandra; Josipa Milardovic; Vedran Stefanovic
Journal:  Transfus Med Hemother       Date:  2019-10-03       Impact factor: 3.747

4.  Molecular characterization of rare D--/D-- variants in individuals of Indian origin.

Authors:  Swati Kulkarni; Garima Mishra; Harita Maru; Disha Parchure; Debasish Gupta; Anantpreet Kaur Bajaj; Sangeeta Pahuja Sindhwani; Anand Chaphekar; Ripal Shah; Claude Férec; Manisha Madkaikar; Yann Fichou
Journal:  Blood Transfus       Date:  2020-11-27       Impact factor: 3.443

Review 5.  Use of umbilical cord serum in ophthalmology.

Authors:  Kyung Chul Yoon
Journal:  Chonnam Med J       Date:  2014-12-17

6.  Ethical Issues and Management of Fetal Hemolytic Anemia Caused by Anti-Rh17 in a Multipara with Rare -D- Phenotype.

Authors:  Patrick P Torreiter; Susanne Macher; Eva-Maria Matzhold; Bernhard Resch; Philipp Klaritsch; Günther F Körmöczi; Helene Polin; Leopold Neuhold; Marlies Schönbacher; Peter Schlenke; Thomas Wagner
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.